gip/glp-1 agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Polyagonists Enable Increasingly Effective Treatment

By week 30, only 28% of people on placebo had an HbA1c (the average blood sugar levels over the last three months) less than 7%, whereas as much as 70% or more of people on any dose of Ozempic achieved an A1C of less than 7%

Naltrexone/Bupropion ER (Contrave): newly approved treatment option for Chronic Weight Management in obese adults

The result is a data asset that allows your team to analyze the full obesity patient journey in one place , without the pain of stitching together fragmented data sources

Report vision changes

Taken from Frias et al

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis